Background: More than 60% of patients diagnosed with MM are > 65 years old and at greater risk for treatment toxicity. Comprehensive geriatric assessment predicts toxicity and survival but is difficult to add to already stressed clinical workflow. We have previously demonstrated feasibility of a tablet-based modified geriatric assessment (mGA). Here, we provide a final report of impact on decision-making and treatment outcomes. Methods: In this multi site study, patients with MM > 65 years old completed a tablet-based mGA in clinic just prior to an oncology visit to discuss a treatment decision. Using the International Myeloma Working Group (IMWG) frailty model, a summary score, along with selected other GA and clinical data, was displayed to oncology providers at the beginning of the clinical visit. Results: 166 patients enrolled. Most were white (76%, n = 127) and male (56%, n = 93); mean age was 72 years (SD6.46; range 61-95). Based on IMWG criteria, patients were fit (39%, n = 64), intermediate fit (33%, n = 55) or frail (28%, n = 47), and 69% of providers agreed/strongly agreed that the mGA influenced the treatment recommendations for the patient. Treatments selected were more intensive for fit patients, while frail patients received lower intensity, with a reduced number of agents or a different route of administration (χ² = 20.81 (4), p < .0001). There was a significant association between fit status and transplant eligibility, with more fit patients being transplant eligible (χ² = 20.81 (6), p = .007). Outcome follow-up at 3 months on 144 patients indicated 39% (n = 56) of patients had a dose modification after the initial assessment and 18% (n = 26) discontinued therapy earlier than planned; 19.4% (n = 28) had a CTCAE grade 3-5 hematologic toxicity and 22% (n = 31) had a grade 3-5 non-hematologic toxicity, most commonly fatigue. Rates of toxicity were similar between patients considered fit, intermediate fit and frail. Conclusions: Results of a mGA presented to a provider at the point of care influenced treatment decisions. Most patients continued the prescribed therapy at 3 months, with relatively low rates of grade 3-5 toxicity. Further study is needed to compare outcomes with standard care. Clinical trial information: NCT03068637